This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GHDX Genomic Health (GHDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Genomic Health Stock (NASDAQ:GHDX) 30 days 90 days 365 days Advanced Chart Get Genomic Health alerts:Sign Up Key Stats Today's Range$63.44▼$63.4450-Day Range$63.44▼$69.7952-Week Range$50.77▼$90.18VolumeN/AAverage Volume1.05 million shsMarket Capitalization$2.38 billionP/E Ratio60.42Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California. Read More Receive GHDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genomic Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GHDX Stock News HeadlinesPanGenomic Health Launches Agenta Health eCommerce Platform and Updates Warrant FinancingAugust 21 at 1:30 PM | tipranks.comPanGenomic Health Unveils AI Platform and Accelerates Warrant ExpirationJuly 25, 2025 | tipranks.comOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. Then an MIT team cracked the code… dropping the cost from $63,000 to just 90 cents per gram. Now, one US-based factory is gearing up to supply the AI, aerospace, and EV industries with the one material they can’t continue to grow without. Only one company controls it, and its stock is still flying under Main Street’s radar. | True Market Insiders (Ad)PanGenomic Health Announces Leadership Changes and Financial UpdatesJuly 11, 2025 | tipranks.comPanGenomic Health Releases 2024 Financial ResultsJuly 2, 2025 | tipranks.comPanGenomic Health Enhances Investor Relations and Updates Warrant ExpirationJune 23, 2025 | tipranks.comPanGenomic Health Updates on Cease Trade Order and Financial FilingsMay 22, 2025 | tipranks.comPanGenomic Health Announces CFO TransitionApril 4, 2025 | tipranks.comSee More Headlines GHDX Stock Analysis - Frequently Asked Questions How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) released its earnings results on Monday, November, 11th. The medical research company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.11. Genomic Health had a trailing twelve-month return on equity of 19.62% and a net margin of 12.81%. What other stocks do shareholders of Genomic Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genomic Health investors own include Revance Therapeutics (RVNC), Horizon Therapeutics Public (HZNP), Illumina (ILMN), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX) and Exelixis (EXEL). Company Calendar Last Earnings11/11/2019Today8/23/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:GHDX CIK1131324 Webwww.genomichealth.com Phone650-556-9300FaxN/AEmployees829Year FoundedN/AProfitability EPS (Trailing Twelve Months)$1.05 Trailing P/E Ratio60.42 Forward P/E Ratio40.15 P/E GrowthN/ANet Income$25.68 million Net Margins12.81% Pretax MarginN/A Return on Equity19.62% Return on Assets14.89% Debt Debt-to-Equity Ratio0.15 Current Ratio5.96 Quick Ratio5.96 Sales & Book Value Annual Sales$394.11 million Price / Sales6.05 Cash Flow$1.45 per share Price / Cash Flow43.76 Book Value$7.48 per share Price / Book8.48Miscellaneous Outstanding Shares37,590,000Free FloatN/AMarket Cap$2.38 billion OptionableOptionable Beta0.90 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:GHDX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genomic Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genomic Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.